Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2

BACKGROUND: Secukinumab treatment has previously been shown to significantly improve the signs and symptoms of active ankylosing spondylitis (AS), with responses sustained through 2 years. Here, we report the long-term (3 years) efficacy and safety of secukinumab in the MEASURE 2 study. METHODS: MEA...

Descripción completa

Detalles Bibliográficos
Autores principales: Marzo-Ortega, Helena, Sieper, Joachim, Kivitz, Alan, Blanco, Ricardo, Cohen, Martin, Delicha, Evie-Maria, Rohrer, Susanne, Richards, Hanno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5761290/
https://www.ncbi.nlm.nih.gov/pubmed/29435364
http://dx.doi.org/10.1136/rmdopen-2017-000592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5761290/
https://www.ncbi.nlm.nih.gov/pubmed/29435364
http://dx.doi.org/10.1136/rmdopen-2017-000592

Ejemplares similares